Russell Greig
Biomedical Sciences
Tigenix
Netherlands
Biography
Dr. Russell Greig worked at GlaxoSmithKline for three decades, most recently as President of SR One, GSK’s Corporate Venture Group. Prior to joining SR One, he served as President of GSK’s Pharmaceuticals International from 2003 to 2008 as well as on the GSK Corporate Executive Team. Dr. Greig currently serves as Chairman of AM Pharma and Mint Solutions in the Netherlands, and as a board member of Ablynx in Belgium, Onxeo Pharma (previously BioAlliance Pharma) in France, and Oryzon in Spain. He also serves as a venture partner at Kurma Life Sciences (Paris, France). Dr. Russell Greig used to be Chairman of Isconova AB in Sweden (acquired by Novavax, USA), Novagali in France (acquired by Santen, Japan), and Syntaxin in the UK (acquired by Ipsen, France).
Research Interest
Dr. Russell Greig worked at GlaxoSmithKline for three decades, most recently as President of SR One, GSK’s Corporate Venture Group. Prior to joining SR One, he served as President of GSK’s Pharmaceuticals International from 2003 to 2008 as well as on the GSK Corporate Executive Team. Dr. Greig currently serves as Chairman of AM Pharma and Mint Solutions in the Netherlands, and as a board member of Ablynx in Belgium, Onxeo Pharma (previously BioAlliance Pharma) in France, and Oryzon in Spain. He also serves as a venture partner at Kurma Life Sciences (Paris, France). Dr. Russell Greig used to be Chairman of Isconova AB in Sweden (acquired by Novavax, USA), Novagali in France (acquired by Santen, Japan), and Syntaxin in the UK (acquired by Ipsen, France).
